aTYR PHARMA INC Share-based Payment Arrangement, Noncash Expense
aTYR PHARMA INC (ATYR) reported Share-based Payment Arrangement, Noncash Expense of $2.47 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2015-11-10
- aTYR PHARMA INC share-based payment arrangement, noncash expense for the quarter ending 2015-09-30 was $1.05M, a 121.99% increase year-over-year.
- aTYR PHARMA INC share-based payment arrangement, noncash expense for the quarter ending 2015-06-30 was $816.00K, a 391.57% increase year-over-year.
- aTYR PHARMA INC share-based payment arrangement, noncash expense for the quarter ending 2015-03-31 was $603.00K, a 313.01% increase year-over-year.
- aTYR PHARMA INC share-based payment arrangement, noncash expense for the quarter ending 2014-09-30 was $473.00K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month |
|---|---|---|---|
| 2015-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $1.87M derived: sum of 2 quarters · filed 2015-11-10 | $2.47M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $816.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $1.42M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $603.00K 10-Q · filed 2015-06-18 | ||
| 2014-09-30 | $473.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $639.00K derived: sum of 2 quarters · filed 2015-11-10 | $785.00K 10-Q · filed 2015-11-10 |
| 2014-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $312.00K 10-Q · filed 2015-08-12 | |
| 2014-03-31 | $146.00K 10-Q · filed 2015-06-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |